Here, we generated a CD1d-Vδ2 bsTCE that can trigger robust activation of both type 1 NKT and Vγ9Vδ2-T cells toward CD1d+ tumor cells, resulting in strong activity in in vivo models and ex vivo against patient multiple myeloma (MM), monocytic acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL) cells. Here, CD1D is linked to acute myeloid leukemia.